RT Journal Article
SR Electronic
T1 Comparison diagnostic value of 18F-FDG PET/MRI and PET/CT in evaluation of pleural invasion in patient with non-small cell lung cancer
JF Journal of Nuclear Medicine
JO J Nucl Med
FD Society of Nuclear Medicine
SP 1029
OP 1029
VO 62
IS supplement 1
A1 Wang, Mali
A1 He, Zhang
A1 Hao-jun, Yu
A1 Hui, Tan
A1 Ling-zhi, Hu
A1 Kong, Han-jing
A1 Mao, Wu-jian
A1 Jie, Xiao
A1 Hong-cheng, Shi
YR 2021
UL http://jnm.snmjournals.org/content/62/supplement_1/1029.abstract
AB 1029Introduction: To compare the diagnostic value of 18F-FDG PET/MRI and PET/CT in assessment of pleural invasion in patient with non-small cell lung cancer. Methods: 52 patients with pathologically confirmed NSCLC were enrolled. Whole-body 18F-FDG PET/CT and subsequent thoracic PET/MR were performed for initial thoracic staging. Thoracic PET/MR acquires PET image simultaneously with sequences including transverse and coronal T2 imaging with fat saturation, transverse and coronal T1 imaging, transverse T2 imaging, and diffusion weighted imaging (DWI). According to the eighth edition of AJCC, two nuclear medicine physicians independently assessed the thoracic T and N staging as well as pleural involvement. The McNemar chi2 Test was used to compare the differences between PET/CT and PET/MR in the evaluation of correct T and N staging and pleural invasion. Results: PET/MR exhibited higher sensitivity, specificity and accuracy in detection of pleural invasion than PET/CT (81.8 % vs. 63.6%, 97.6 % vs. 95.1%, 94.2% vs. 88.5%) respectively. T staging results were concordant in 18F-FDG PET/CT and 18F-FDG PET/MR (accuracy: 84.6 % vs. 82.7 %), respectively. N staging results were concordant in 18F-FDG PET/CT and 18F-FDG PET/MR and the accuracies of N staging were 88.5% (46/52). Differences between 18F-FDG PET/CT and PET/MRI in T staging, N staging accuracy as well as pleural invasion were not statistically significant (p > 0.5, each). Conclusions: PET/MR was comparable to PET/CT in evaluation of pleural invasion as well as preoperative staging of patients with non-small cell lung cancer, whereas with advantages for PET/MR by trend. Acknowledgements: This study is supported by the Shanghai Municipal Key Clinical Specialty (No.shslczdzk03401), Three-year Action Plan of Clinical Skills and Innovation of Shanghai Hospital Development Center (No. SHDC2020CR3079B), and the shanghai Science and Technology Committee (No. 19DZ1930702). Key research program “Development of Digital Diagnostic and Therapeutic Equipment” (NO. 2016YFC0103900), Ministry of Science and Technology of People’s Republic of China.United Imaging Research gave some advice to this study.